372 related articles for article (PubMed ID: 33822354)
1. Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
Harada T; Iwasaki H; Muta T; Urata S; Sakamoto A; Kohno K; Takase K; Miyamura T; Sawabe T; Asaoku H; Oryoji K; Fujisaki T; Mori Y; Yoshimoto G; Ayano M; Mitoma H; Miyamoto T; Niiro H; Yamamoto H; Oshiro Y; Miyoshi H; Ohshima K; Takeshita M; Akashi K; Kato K
Br J Haematol; 2021 Jul; 194(1):101-110. PubMed ID: 33822354
[TBL] [Abstract][Full Text] [Related]
2. Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders.
Nakano K; Saito K; Nawata A; Hanami K; Kubo S; Miyagawa I; Fujino Y; Nakayamada S; Tanaka Y
Mod Rheumatol; 2021 Jan; 31(1):94-100. PubMed ID: 32159414
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate-associated lymphoproliferative disorder in the stomach and duodenum: a case report.
Toyonaga H; Fukushima M; Shimeno N; Inokuma T
BMC Gastroenterol; 2019 Apr; 19(1):62. PubMed ID: 31023238
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression.
Ichikawa A; Arakawa F; Kiyasu J; Sato K; Miyoshi H; Niino D; Kimura Y; Takeuchi M; Yoshida M; Ishibashi Y; Nakashima S; Sugita Y; Miura O; Ohshima K
Eur J Haematol; 2013 Jul; 91(1):20-8. PubMed ID: 23560463
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: Comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types.
Gion Y; Iwaki N; Takata K; Takeuchi M; Nishida K; Orita Y; Tachibana T; Yoshino T; Sato Y
Cancer Sci; 2017 Jun; 108(6):1271-1280. PubMed ID: 28380678
[TBL] [Abstract][Full Text] [Related]
6. Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study.
Nakano K; Tanaka Y; Saito K; Kaneko Y; Saito S; Tanaka M; Saito R; Fujii T; Kuramoto N; Sugimoto N; Takada H; Harigai M; Sasaki S; Suzuki Y
Mod Rheumatol; 2022 Jan; 32(1):41-49. PubMed ID: 33164614
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression is associated with the spontaneous regression of patients with methotrexate-associated lymphoproliferative disorders.
Gion Y; Doi M; Nishimura Y; Ikeda T; Filiz Nishimura M; Sakamoto M; Egusa Y; Nishikori A; Fujita A; Iwaki N; Nakamura N; Yoshino T; Sato Y
Cancer Med; 2022 Jan; 11(2):417-432. PubMed ID: 34842351
[TBL] [Abstract][Full Text] [Related]
8. Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients.
Saito S; Takeuchi T
J Clin Exp Hematop; 2019; 59(4):145-155. PubMed ID: 31866617
[TBL] [Abstract][Full Text] [Related]
9. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.
Hoshida Y; Xu JX; Fujita S; Nakamichi I; Ikeda J; Tomita Y; Nakatsuka S; Tamaru J; Iizuka A; Takeuchi T; Aozasa K
J Rheumatol; 2007 Feb; 34(2):322-31. PubMed ID: 17117491
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors.
Kurita D; Miyoshi H; Ichikawa A; Kato K; Imaizumi Y; Seki R; Sato K; Sasaki Y; Kawamoto K; Shimono J; Yamada K; Muto R; Kizaki M; Nagafuji K; Tamaru JI; Tokuhira M; Ohshima K
Am J Surg Pathol; 2019 Jul; 43(7):869-884. PubMed ID: 31116708
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate-associated Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis Successfully Treated with Brentuximab Vedotin in Combination with Doxorubicin, Vinblastine, and Dacarbazine (BV+AVD).
Sekiguchi Y; Iizuka H; Takizawa H; Sugimoto K; Sakajiri S; Inano T; Fukuda Y; Shirane S; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Sekiguchi N; Noguchi M
Intern Med; 2020 Sep; 59(17):2165-2171. PubMed ID: 32461524
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents.
Katsuyama T; Sada KE; Yan M; Zeggar S; Hiramatsu S; Miyawaki Y; Ohashi K; Morishita M; Watanabe H; Katsuyama E; Takano-Narazaki M; Toyota-Tatebe N; Sunahori-Watanabe K; Kawabata T; Miyake K; Kiguchi T; Wada J
Mod Rheumatol; 2017 Sep; 27(5):773-777. PubMed ID: 27846761
[TBL] [Abstract][Full Text] [Related]
13. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients.
Kameda T; Dobashi H; Miyatake N; Inoo M; Onishi I; Kurata N; Mitsunaka H; Kawakami K; Fukumoto T; Susaki K; Izumikawa M; Nakashima S; Shimada H; Takeuchi Y; Haba R; Mano S; Onishi H; Imataki O; Matsunaga T
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1302-9. PubMed ID: 24515570
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological features of clinical methotrexate-related lymphoproliferative disorders.
Tokuhira M; Saito S; Suzuki K; Higashi M; Momose S; Shimizu T; Mori T; Kimura Y; Amano K; Okamoto S; Takeuchi T; Tamaru JI; Kizaki M
Leuk Lymphoma; 2019 Oct; 60(10):2508-2515. PubMed ID: 30947579
[TBL] [Abstract][Full Text] [Related]
15. Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis.
Tanaka K; Ichikawa A; Umezawa N; Yamamoto K; Yoshifuji K; Okada K; Nogami A; Umezawa Y; Nagao T; Sakashita C; Mori T; Tohda S; Koike R; Yasuda S; Yamamoto M
Cancer Sci; 2023 Sep; 114(9):3719-3727. PubMed ID: 37365854
[TBL] [Abstract][Full Text] [Related]
16. Mature T/NK-cell lymphoproliferative disease and Epstein-Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate.
Kondo S; Tanimoto K; Yamada K; Yoshimoto G; Suematsu E; Fujisaki T; Oshiro Y; Tamura K; Takeshita M; Okamura S
Virchows Arch; 2013 Apr; 462(4):399-407. PubMed ID: 23494713
[TBL] [Abstract][Full Text] [Related]
17. A case of multiple hepatic lesions associated with methotrexate-associated lymphoproliferative disorder.
Matsumoto R; Numata K; Doba N; Hara K; Chuma M; Fukuda H; Nozaki A; Tanaka K; Ishii Y; Maeda S
J Med Ultrason (2001); 2016 Oct; 43(4):545-51. PubMed ID: 27577564
[TBL] [Abstract][Full Text] [Related]
18. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
Smolen JS; Landewé R; Bijlsma J; Burmester G; Chatzidionysiou K; Dougados M; Nam J; Ramiro S; Voshaar M; van Vollenhoven R; Aletaha D; Aringer M; Boers M; Buckley CD; Buttgereit F; Bykerk V; Cardiel M; Combe B; Cutolo M; van Eijk-Hustings Y; Emery P; Finckh A; Gabay C; Gomez-Reino J; Gossec L; Gottenberg JE; Hazes JMW; Huizinga T; Jani M; Karateev D; Kouloumas M; Kvien T; Li Z; Mariette X; McInnes I; Mysler E; Nash P; Pavelka K; Poór G; Richez C; van Riel P; Rubbert-Roth A; Saag K; da Silva J; Stamm T; Takeuchi T; Westhovens R; de Wit M; van der Heijde D
Ann Rheum Dis; 2017 Jun; 76(6):960-977. PubMed ID: 28264816
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate-related lymphoproliferative disorder of the stomach in a patient with rheumatoid arthritis: a case of disease regression after methotrexate cessation.
Ikeda K; Nakamura T; Kinoshita T; Fujiwara M; Uose S; Someda H; Miyoshi T; Io K; Nagai K
Clin J Gastroenterol; 2016 Feb; 9(1):17-21. PubMed ID: 26733461
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus infection and gene promoter hypermethylation in rheumatoid arthritis patients with methotrexate-associated B cell lymphoproliferative disorders.
Ejima-Yamada K; Oshiro Y; Okamura S; Fujisaki T; Mihashi Y; Tamura K; Fukushige T; Kojima M; Shibuya K; Takeshita M
Virchows Arch; 2017 Feb; 470(2):205-215. PubMed ID: 27864689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
